25 junio 2007
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Junio 2007 .
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
23 junio 2007
22 junio 2007
21 junio 2007
NeuroPharma Patente : Dibenzene derivatives as calcium channel blockers .
Dibenzene derivatives as calcium channel blockers
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
19 junio 2007
18 junio 2007
Joan Vericat , de NeuroPharma , en Euronanoforum ( Alemania ) 19 al 21 Junio . Nanotechnology in Life .
Poster :
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
P-C10
SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)
Suscribirse a:
Entradas (Atom)